An Introduction to Endocrine Oncology
Endocrine oncology encompasses malignancies of hormone-producing glands such as the thyroid, parathyroid, pituitary and adrenal gland, as well as endocrine tumours of the gastrointestinal tract and pancreas. While some of these malignancies are relatively rare, thyroid cancer is the most commonly diagnosed cancer in people aged 15–29 years. These cancers present a therapeutic challenge as chemotherapy is often ineffective, and the proliferation rate and the mutational load are usually very low. Advances include small-molecule kinase inhibitors, I-124-positron emission tomography and computed X-ray tomography-based selection of optimal therapeutic strategies, peptide receptor radionuclide therapy with somatostatin receptor antagonists, cell-based therapies and novel immunotherapies.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Endocrine Oncology Content
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity.
- Describe the underlying rationale and mechanism of action for radiopharmaceuticals in adult oncology
- Recall the different types of radiopharmaceuticals (approved and in clinical development), and their specific properties
Surgical Treatment of Solitary Metachronous Adrenal Metastasis from Urothelial Carcinoma of the Urinary Bladder
touchREVIEWS in Endocrinology. 2023;19(1):94-7 DOI: https://doi.org/10.17925/EE.2023.19.1.94
Bladder cancer (BC) is the second most commonly diagnosed urological neoplasm worldwide.1 Approximately 10–15% of patients already have metastases in lymph nodes, lungs, liver and bones at diagnosis.2,3 Metastatic BC has a poor prognosis, with a 5-year overall survival (OS) rate of 10% and median OS of only 15 months.4–6 The vast majority (>90%) of BCs are urothelial […]
Ashley Grossman: Research highlights from 2022 in neuroendocrine tumours
New exciting therapies for neuroendocrine tumours include the introduction of RET inhibitors for medullary thyroid cancer and belzutifan for metastatic pancreatic neuroendocrine tumours. We were delighted to speak with our editorial board member Prof. Ashley Grossman (University of Oxford, Oxford, UK) around this year’s research highlights in these topics and what to look out for […]
Advancing the multidisciplinary management of rare and unusual NETs: Integrating new approaches to treatment and care
Watch leading specialists involved in the multidisciplinary care of patients with rare and unusual neuroendocrine tumours discuss new and emerging approaches for diagnosis and treatment.
- Recognize the role of the MDT in addressing diagnostic and treatment challenges associated with rare and unusual neuroendocrine tumours (NETs)
- Evaluate the factors guiding treatment selection and clinical management decisions in rare and unusual NETs
- Appraise the efficacy and safety of new and emerging treatment options for rare and unusual NETs
A New Medical Therapy for Multiple Endocrine Neoplasia Type 1?
touchREVIEWS in Endocrinology. 2022;18(2):86-8 DOI: https://doi.org/10.17925/EE.2022.18.2.86
Multiple endocrine neoplasia type 1 (MEN1) is an inherited tumour endocrine syndrome, with the parathyroid glands, anterior pituitary gland and pancreas as the main sites of MEN1-related neuroendocrine tumours (NETs). MEN1 is inherited in an autosomal dominant manner, with 90% of individuals diagnosed with this disease having an affected parent, while only 10% have a de […]
Personalized treatment of RET-altered thyroid cancers: What is the value of biomarker testing and targeted therapies?
Leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
- Distinguish between different types of thyroid cancers and describe therapies that are appropriate for their management
- Plan a personalized approach to treatment of RET-altered thyroid cancers, including use of biomarker testing and novel targeted therapies
- Evaluate the clinical trial data for novel targeted therapies for RET-altered thyroid cancers and apply it to clinical practice
Perspectives on the current status and recent advances in GEP-NETs
Explore current perspectives on the management of GEP-NETs through this panel discussion, highlighting emerging data presented at the ESMO Congress 2021.
Optimizing the management of gastroenteropancreatic neuroendocrine tumours
Watch leading experts explore how recent scientific and clinical advances may optimize the medical management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in 2021, and beyond.
Camilo Jimenez, ENDO 2021: The Role of Tumour Biomarkers in the use of I-131MIBG
It was a pleasure to talk to Professor Camilo Jimenez (The University of Texas MD Anderson Cancer Center, Houston, TX) around biochemical tumour markers in the use of I-131-labeled MIBG for pheochromocytoma and paraganglioma. ‘Biochemical Tumor Marker Status and Its Role in Treatment Response in Patients Who Received High-Specific-Activity I-131 MIBG in Advanced Pheochromocytoma and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!